Improving Dialysis Adherence for High Risk Patients Using Automated Messaging: Proof of Concept
We were able to demonstrate the feasibility of implementing EpxDialysis within the chronic hemodialysis population. The trends suggest that the intervention has potential to improve adherence with medically-prescribed dialysis treatment.
Assessing the Utility of a Novel SMS- and Phone-Based System for Blood Pressure Control in Hypertensive Patients: Feasibility Study
Epharmix’s EpxHypertension, a bidirectional automated phone and text messaging service, is well accepted by both patients and providers in a community clinic setting based on response rate and patient satisfaction survey results. It has demonstrated feasibility by helping higher-risk hypertensive patients (ie, higher baseline BPs) achieve capturable BP reductions.
Improving Glycemic Control With a Standardized Text-Message and Phone-Based Intervention: A Community Implementation
The results of this study suggest that EpxDiabetes is an inexpensive, low-risk, noninvasive intervention that can be implemented in a variety of settings to accelerate glycemic control for patients with T2DM with baseline HbA1c >8%. The results merit future investigation of the long-term effects of EpxDiabetes on patient health outcomes.
EpxMedTracking: Feasibility Evaluation of an SMS-Based Medication Adherence Tracking System in Community Practice
EpxMedTracking is an effective tool for tracking self-reported medication adherence over time. It uniquely identifies actionable reasons for missing doses for subsequent provider intervention in real time based on patient feedback. Patients enrolled on EpxMedTracking also self-report higher rates of medication adherence over time while on the system.
Phone-Based Interventions in Adolescent Psychiatry: A Perspective and Proof of Concept Pilot Study With a Focus on Depression and Autism
Text-message interventions in adolescent psychiatry can provide a cost-effective and engaging method to track symptoms, behavior, and ideation over time. Following the collection of pilot data and feedback from providers and patients, larger studies are already underway to validate the clinical utility of EpxDepression and EpxAutism.